Franklin Biotechnology Discovery Fund Class R6 (FRBRX)

Fund Assets	1.42B
Expense Ratio	0.69%
Min. Investment	$1,000,000
Turnover	n/a
Dividend (ttm)	11.76
Dividend Yield	9.70%
Dividend Growth	n/a
Payout Frequency	n/a
Ex-Dividend Date	Dec 20, 2024

Previous Close	120.27
YTD Return	-5.70%
1-Year Return	2.79%
5-Year Return	6.20%
52-Week Low	n/a
52-Week High	n/a
Beta (5Y)	n/a
Holdings	92
Inception Date	May 1, 2013

About FRBRX

The Franklin Biotechnology Discovery Fund Class R6 (FRBRX) seeks to provide capital appreciation. Under normal market conditions, the Fund predominantly invests in equity securities and invests at least 80% of its net assets in securities of biotechnology companies(at least 50% of its earnings derived from biotechnology activities) and discovery research firms.

• Category: Health
• Performance Rating: Average
• Risk Rating: Above Average
• Stock Exchange: NASDAQ
• Ticker Symbol: FRBRX
• Share Class: Class R6
• Index: NASDAQ Biotechnology CR

Performance

FRBRX had a total return of 2.79% in the past year, including dividends. Since the fund's inception, the average annual return has been 6.21%.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
FTDZX	Advisor Class	0.80%
FBDIX	Class A	1.05%
FBTDX	Class C	1.80%

Top 10 Holdings

50.13% of assets

Name	Symbol	Weight
Amgen Inc.	AMGN	8.11%
Gilead Sciences, Inc.	GILD	7.82%
Vertex Pharmaceuticals Incorporated	VRTX	7.75%
Regeneron Pharmaceuticals, Inc.	REGN	5.50%
Ascendis Pharma A/S	ASND	4.42%
Jazz Pharmaceuticals plc	JAZZ	4.10%
argenx SE	ARGX	3.80%
PTC Therapeutics, Inc.	PTCT	3.13%
Merus N.V.	MRUS	2.93%
Neurocrine Biosciences, Inc.	NBIX	2.57%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 20, 2024	$11.7607	Dec 20, 2024
Dec 20, 2022	$0.5857	Dec 20, 2022
Dec 15, 2021	$18.2831	Dec 15, 2021
Dec 15, 2020	$10.3921	Dec 15, 2020
Dec 16, 2019	$14.1643	Dec 18, 2019
Dec 17, 2018	$4.5496	Dec 19, 2018